Feliza Mirasol

Data from a Phase III trial showed durable survival benefit with PD-L1 blockade plus chemotherapy, reinforcing the use of immunotherapy in curative-intent GI cancer settings.

Today’s podcast explores how late-stage clinical evidence supports extending established biologics into adjacent inflammatory diseases, reinforcing platform-based development strategies.

Regulatory acceptance of tildrakizumab's sBLA signals a potential expansion of IL-23 inhibition into joint disease, an area in which treatment gaps persist for a substantial share of psoriatic disease patients.

The companies’ new immunology-driven mAb, which targets an immune-evasion pathway in myeloproliferative neoplasms, is advancing toward first-in-human trials.

The company is targeting the $3 billion pancreatic cancer market with its lead proenzyme therapy candidate, PRP, which is supported by strong preclinical tumor inhibition data and for which a PK assay will be developed and validated.

Results from a head-to-head study highlight cytokine-targeting differences between UCB’s bimekizumab and risankizumab, strengthening evidence for dual IL-17 blockade in psoriatic arthritis therapy

The new clinical data show biomarker reductions and new motor milestones with salanersen, which supports once-yearly antisense therapy development in spinal muscular atrophy.

Data from the MajesTEC-9 Phase III trial shows teclistamab as monotherapy improves survival, indicating a shift in multiple myeloma treatment.

The launch of a new mRNA biotech spinout signals a structural shift in how next-generation RNA therapeutics are developed and commercialized.

Today’s podcast covers Phase II trispecific antibody data and evolving ADC strategies, which highlight durable, patient-centric approaches reshaping next-generation oncology therapy pipelines.

In a Phase II trial, Pfizer’s tilrekimig demonstrated well-tolerated, dose-dependent improvements in chronic Th2 inflammation, supporting further clinical development in atopic dermatitis.

Phase III trial results show that trastuzumab deruxtecan reduced invasive recurrence or death 53% in patients with residual HER2-positive disease after neoadjuvant therapy.

China’s approval of Sciwind’s ecnoglutide for weight management, alongside the company’s Pfizer commercialization deal, intensifies competition in the global GLP-1 market.

In today’s podcast, integrated biomarker modeling and dual-pathway immune checkpoint modulation highlight evolving strategies to improve translational efficiency and durability in oncology trials.

Updated analysis from the COMPASSION-03 Phase II trial links response depth to survival, which supports PD-1/CTLA-4 bispecific checkpoint strategies in heavily pretreated cervical cancer.

Advanced data strategies and specialist biometrics teams can deliver faster, cleaner insights from Phase I trials and power smarter early drug decisions, says Ben Edwards of Avance Clinical.

INOVIO and Akeso’s combination of DNA tumor antigen priming and dual checkpoint inhibition exemplifies adaptive trial strategies for challenging glioblastoma therapy.

Under the partnership, INOVIO and Akeso will evaluate DNA-encoded tumor antigen priming plus PD-1/CTLA-4 bispecific blockade in an adaptive Phase II trial for glioblastoma.

Avance Clinical’s Ben Edwards explains how biotechs must design Phase I trials for quantitative exposure–response data to meet current FDA guidance and de‑risk Phase II dose selection.

Today’s podcast covers how integrated development models and multi-pathway therapeutic design are signaling a shift toward scalable, system-ready biopharma innovation and translational efficiency.

Data from Novo Nordisk’s UBT251 Phase II trial support triple-receptor metabolic modulation as a strategy to enhance weight-loss efficacy beyond single-pathway incretin therapies.

CGT Catapult’s newly formed advisory board aims to address manufacturing, data, and regulatory constraints influencing scalable development and clinical deployment of ATMPs.

Clinical trial execution and workforce strategy emerge as critical drivers of successful rare disease and advanced therapy development outcomes.

Roche’s termination of the SHIELD DMD trial highlights how recruitment and regulatory feasibility increasingly shape rare disease drug development.

In the final installment of an interview with Cardinal Health’s Anna Catalanotto, she discusses how leveraging real-world evidence and advanced value-based reimbursement models can optimize clinical adoption and long-term sustainability of CGTs.

Today’s podcast highlights how sustained clinical efficacy data in alpha-thalassemia and ulcerative colitis highlight durability as a defining benchmark in modern biologic drug development.

Long-term data from a Johnson & Johnson study show that sustained IL-23 inhibition maintains histologic and endoscopic remission, supporting durability-driven UC drug development strategies.

Bristol Myers Squibb’s luspatercept-aamt data validate erythroid maturation targeting, supporting scalable development strategies for genetic anemia therapeutics.

Welcome to BioPharm Brief, a new podcast that synthesizes BioPharm International®’s coverage into concise, insight-driven updates on biopharmaceutical research, clinical and drug development trends, and evolving industry strategies.

FDA’s priority review designation of Regeneron Pharmaceuticals’ garetosmab underscores Activin A inhibition as a potential disease-modifying strategy for genetically driven ossification disorders.